Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting.

MLA

Belaroussi, Yaniss, et al. “Survival Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Receiving Chemotherapy or Immunotherapy as First-Line in a Real-Life Setting.” Scientific Reports, vol. 13, no. 1, June 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1038/s41598-023-36623-1.

APA

Belaroussi, Y., Bouteiller, F., Bellera, C., Pasquier, D., Perol, M., Debieuvre, D., Filleron, T., Girard, N., Schott, R., Mathoulin-Pélissier, S., Martin, A.-L., & Cousin, S. (2023). Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Scientific Reports, 13(1), 1–11. https://doi.org/10.1038/s41598-023-36623-1

Chicago

Belaroussi, Yaniss, Fanny Bouteiller, Carine Bellera, David Pasquier, Maurice Perol, Didier Debieuvre, Thomas Filleron, et al. 2023. “Survival Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Receiving Chemotherapy or Immunotherapy as First-Line in a Real-Life Setting.” Scientific Reports 13 (1): 1–11. doi:10.1038/s41598-023-36623-1.